The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Expression of immune checkpoints (ICs) on circulating tumor cells (CTCs) in men with metastatic prostate cancer (mPC).
 
Tian Zhang
Leadership - Capio BioSciences (I)
Stock and Other Ownership Interests - Capio Biosciences (I)
Consulting or Advisory Role - AstraZeneca; Bayer; Exelixis; G1 Therapeutics; Genentech/Roche; Janssen; Sanofi
Speakers' Bureau - Exelixis
Research Funding - Acerta Pharma (Inst); Janssen (Inst); Merrimack (Inst); Novartis (Inst); OmniSeq (Inst); Personal Genome Diagnostics (Inst); Pfizer (Inst); Stem CentRx (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture by c-MET technology (Inst)
Travel, Accommodations, Expenses - Acerta Pharma
 
Rebecca Garland Austin
No Relationships to Disclose
 
Sally E Park
No Relationships to Disclose
 
Daniella Runyambo
No Relationships to Disclose
 
Rengasamy Boominathan
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Chandra Rao
Employment - Janssen
Stock and Other Ownership Interests - Johnson & Johnson
 
Elizabeth Bronson
No Relationships to Disclose
 
Monika Anand
No Relationships to Disclose
 
Patrick Healy
No Relationships to Disclose
 
Daniel J. George
Honoraria - Axess Oncology; Bayer; BIOPHARM; Dendreon; Medivation; Novartis; Sanofi
Consulting or Advisory Role - Acceleron Pharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Celgene; Dendreon; Exelixis; Genentech; GlaxoSmithKline; Innocrin Pharma; Janssen; Medivation; Merck Sharp & Dohme; Myovant Sciences; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Exelixis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); Innocrin Pharma; Janssen Oncology (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Genentech/Roche; Medivation; Merck; Pfizer
 
Megan Ann McNamara
Research Funding - Agensys; Bayer; Clovis Oncology; Janssen; Seattle Genetics/Astellas
Travel, Accommodations, Expenses - Agensys; Clovis Oncology
 
Andrew J. Armstrong
Honoraria - Dendreon; Janssen Oncology; Sanofi
Consulting or Advisory Role - Bayer; Dendreon; Janssen Biotech; Medivation; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Dendreon; Sanofi
Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Bayer; Dendreon; Janssen Biotech; Medivation; Sanofi